MLYS (Mineralys Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLYS Mineralys Therapeutics Inc MLYS
37 GF Score
Price $27.09
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics 5-Year Yield-on-Cost %?

Mineralys Therapeutics MLYS +0.04% 37 5-Year Yield-on-Cost % is 0.00 as of Jul. 19, 2026. GuruFocus rates MLYS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 153 Biotechnology companies, Mineralys Therapeutics ranks worse than 653594.12% on this metric.

Mineralys Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Mineralys Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



MLYS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Mineralys Therapeutics  (NAS:MLYS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Mineralys Therapeutics 5-Year Yield-on-Cost % Related Terms

MLYS vs VCEL, NRIX, PHVS: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Mineralys Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's 5-Year Yield-on-Cost % falls into.


MLYS
37GF Score
Mineralys Therapeutics Inc MLYS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Mineralys Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Mineralys Therapeutics (MLYS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry.
Is Mineralys Therapeutics' 5-Year Yield-on-Cost % too high?
Mineralys Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Mineralys Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' 5-Year Yield-on-Cost % compare to VCEL and NRIX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Mineralys Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.73, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Mineralys Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mineralys Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Mineralys Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
37GF Score

Get the complete analysis for MLYS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.09
Price